Novo Nordisk
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source. This covers Novo Nordisk A/S, the operating company. Novo Holdings and the Novo Nordisk Foundation are separate entities, and their deals are left out unless Novo Nordisk A/S is itself a party.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | 8 | 4 | live | 4 | 2 |
| Research labs and data | 2 | 2 | funded or contracted | 0 | 2 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
AI in drug discovery scores 8 out of 10 for priority at Novo Nordisk and 4 out of 10 for delivery, with work shown live. Its 2026 material lists AI achievements across R&D, including a pre-clinical asset found with machine-learning-assisted design, and an AWS co-innovation hub in London is operating. In the last 12 months it made public four AI commitments, partnerships with OpenAI, AWS and Anthropic and a macrocycle discovery deal with Orbis Medicines, after six in the year before, including Gefion supercomputer access with NVIDIA and OpenFold3 co-development. Research labs and data scores 2 out of 10 for priority and 2 out of 10 for delivery, at the funded or contracted stage, resting mainly on the AWS agreement to connect genomic, imaging and clinical data; no research labs and data commitment was identified in either year. On 6 October 2026 it had 2 open R&D roles tied to each theme, including a senior automation and screening scientist.
AI in drug discovery
What the company says: Priority 8
Key research & development enablers ... End-to-end AI ... and data science
Capital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 3
Significant changes in our R&D set-up ... and AI capabilities to deliver at quality ... and pace
Capital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 14
External innovation is a key enabler to expand the pipeline and strengthen competencies in AI ... Partnering with leading AI providers
Capital Markets Day 2026: Corporate strategy presentation, 21 Sep 2026, p. 12
This partnership is another testament to our ambition to become the world's most AI-driven healthcare company ... Joining forces with Anthropic will supercharge our R&D organisation
Novo and Anthropic will collaborate to advance drug discovery with Claude, 16 Sep 2026
Novo Nordisk and AWS have created a co-innovation hub in London ... to compress the path from drug target to first human dose ... a dedicated co-innovation hub within our existing facility in London
R&D strategy ... Martin Holst Lange ... CSO, EVP, Research & Development ... Mishal Patel ... GVP, AI & Digital Innovation
Capital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 1
Leverage AI/digital capabilities throughout drug discovery process
Investor presentation, first nine months of 2025, 5 Nov 2025, p. 29
we have created a more seamless, end-to-end engine with the 2025 reconfiguration of our R&D organisation. This integrated approach, enhanced by AI and digital technologies, accelerates our pipeline and decision-making
Novo Nordisk Annual Report 2025, 4 Feb 2026, p. 26
Three commitments drive our strategy ... Grow and diversify ... pipeline ... Drive sustainable ... growth ... Deliver attractive ... returns
Capital Markets Day 2026: Corporate strategy (Doustdar), 21 Sep 2026, p. 4
What it shows running: Delivery 4, live
AI is leveraged to improve speed, success and productivity across the research & development value chain Select achievements in 2026
Capital Markets Day 2026: R&D strategy presentation, 21 Sep 2026, p. 7
Pre-clinical asset identified with key outputs ... Combine human-designed sequences with ML-assisted design in an ... active-learning loop
Capital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 8
Novo Nordisk and AWS have created a co-innovation hub in London ... to compress the path from drug target to first human dose ... a dedicated co-innovation hub within our existing facility in London
As an initial aim, Novo will test Claude Science for specific workflows in R&D
Novo and Anthropic will collaborate to advance drug discovery with Claude, 16 Sep 2026
Pilot programmes will launch across research & development, manufacturing and commercial operations, with full integration by the end of 2026.
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered, 14 Apr 2026
Achievements are representative of use cases ... Source: Novo data on file
Capital Markets Day 2026: R&D strategy presentation, 21 Sep 2026, p. 7
Powered ... by ... proprietary data ... and models ... >30 ... strategic partnerships
Capital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 7
AI is leveraged to improve speed, success and productivity across ... the research & development value chain ... Select achievements in 2026 ... >3x ... improved target hit rate by prioritising ... genes found in virtual assays
Capital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 7
Evaluating more molecules and targets, with AI-enabled prioritisation ... weeks in a DMTA ... molecules ... >3x more ... tested on average 4 cycle ... Note: Achievements are representative of use cases
Capital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 7
accelerated the design of a ... amylin with faster and fewer cycles ... Proof of concept for a scalable, AI-enabled drug design model ... ~60% fewer ... DMTA cycles ... -50% ... time to candidate
Capital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 8
Commitments made public in the last 12 months: 4
- Orbis Medicines AI-enabled macrocycle discovery collaboration and investment: Collaboration and licence to discover oral macrocycles using Orbis AI-enabled platform, with a Novo strategic investment in Orbis. New, announced, 17 Sep 2026. Published by: partner release, company quoted.
- Anthropic drug discovery collaboration: Collaboration to apply Anthropic models and Claude Science to drug discovery challenges and R&D workflows, plus software engineering. New, announced, 16 Sep 2026. Published by: joint release.
- AWS strategic AI partnership and London co-innovation hub: AI co-innovation hub in London where AWS and Novo Nordisk staff use AWS AI with Novo data for discovery. New, operational, 10 Aug 2026. Published by: joint release.
- OpenAI strategic partnership: Strategic partnership to apply OpenAI capabilities from drug discovery to commercial operations; pilots to launch, integration by end-2026. New, announced, 14 Apr 2026. Published by: company.
Commitments made public in the year before: 6
- Gefion AI supercomputer access (DCAI) and NVIDIA AI drug discovery collaboration: NVIDIA collaboration to build custom AI models (BioNeMo, NIM, NeMo, Omniverse) for Novo Nordisk research on Gefion. New, announced, 11 Jun 2025. Published by: partner release, company quoted.
- Deep Apple Therapeutics ML virtual screening GPCR collaboration: Research collaboration and licence where Deep Apple discovers compounds with machine-learning virtual screening and cryo-EM. New, announced, 11 Jun 2025. Published by: partner release, company quoted.
- OpenFold Consortium membership and OpenFold3 co-development: Novo Nordisk joined the OpenFold Consortium (open-source AI protein structure models) as one of eight new members. New, announced, 15 Apr 2025. Published by: joint release.
- Gensaic AI protein design ligand discovery collaboration: Licence and discovery collaboration using Gensaic AI-powered protein design to find tissue-targeting ligands. New, announced, 3 Mar 2025. Published by: partner only.
- Valo Health AI-enabled cardiometabolic discovery collaboration: Expanded agreement adds nine programmes to the 2023 Valo collaboration built on AI computation and human data. Expanded, announced, 8 Jan 2025. Published by: joint release.
- Variant Bio genetics and machine-learning target discovery collaboration: Multi-year collaboration using Variant Bio VB-Inference platform (statistical genetics and machine learning) to identify metabolic disease targets. New, announced, 7 Jan 2025. Published by: partner release, company quoted.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 2
- Data Science Specialist, Computational Real-World Evidence (cRWE), Data Science, London, United Kingdom, London
- PKPD Senior Principal Scientist, Denmark, Måløv
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Research labs and data
What the company says: Priority 2
This includes using services such as Amazon Bio Discovery and Amazon Bedrock to identify drug targets, design new therapies faster, and connect genomic, imaging and clinical data
Research activities further utilise digital scientific methodologies and other technology platforms
Novo Nordisk Annual Report 2025 (incl. sustainability statement), 4 Feb 2026, p. 91
Faster, standardised ... execution ... Simplifying and automating core ... processes
Capital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 7
What it shows running: Delivery 2, funded or contracted
Agreement establishes AWS as Novo Nordisk's preferred cloud provider and strategic AI partner to accelerate drug discovery and modernise its technology infrastructure
This includes using services such as Amazon Bio Discovery and Amazon Bedrock to identify drug targets, design new therapies faster, and connect genomic, imaging and clinical data
Research activities further utilise digital scientific methodologies and other technology platforms
Novo Nordisk Annual Report 2025 (incl. sustainability statement), 4 Feb 2026, p. 91
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 2
- Principal Scientist, Functional Genomics, United Kingdom, Oxford
- Senior Automation & Screening Scientist, United Kingdom, Oxford
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Two questions to investigate (Ortent's interpretation)
- Novo Nordisk has four AI arrangements with stated discovery scope (Gefion with NVIDIA, OpenAI, AWS and Anthropic), and AI leadership sits in several places: a Chief AI Officer, an AI and Digital Innovation organisation, an AI product engineering team and R&D IT architecture. Who chooses AI models and compute for discovery, and does a discovery team's AI purchase go through the AWS preferred-provider agreement, R&D IT or another route?
- Lab automation for target discovery sits at the Oxford research centre, lab IT for quality labs sits in Enterprise IT and Quality, and the enterprise data platform is built on Databricks. Who decides on new screening automation and lab data tools for research labs, and how is that funded while the company runs a cost-saving transformation?
Coverage limits
Business Wire blocked access and GlobeNewswire did not respond, so no partner release was read from either; the Gensaic and Eikonizo releases were read only as summaries, and the OpenFold release only through the consortium page and a media report. Fierce Biotech, Pharmaceutical Technology and AI Magazine also blocked access, so the Gensaic deal value is not recorded. Earnings call transcripts are not published on the company site and were not searched for elsewhere, and three company pages carry no date. Novo Nordisk's own releases and annual reports were read in full, so the gaps sit mainly in partner announcements.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call